COMMUNIQUÉS West-GlobeNewswire

JavaTide Examined: 2026 Analysis of Ingredients Profile, Dosage Accuracy, and Metabolic Support Claims
21/05/2026
Comprehensive Evaluation Examines JavaTide Formula, Manufacturing Standards, and Consumer Verification Data for Gut Health Supplement Market Austin, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
SlimTide Examined: 2026 Consumer-Focused Analysis of Ingredients, Claims, and Label Transparency
21/05/2026
Gut Microbiome Support Formula with Chicory Inulin, Resistant Starch, and Akkermansia Muciniphila Explained for Consumer Research Miami, FL, May 21, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by [...]
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
21/05/2026
Copenhagen, Denmark, 21 May 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the appointment of Philip Just [...]
Hanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast Asia
21/05/2026
Cardiovascular and Respiratory medicines to be supplied in Malaysia and the Philippines Shin Hae-gon (right), Head of Overseas Sales at Hanmi Pharmaceutical, and Andreas Daugaard Jørgensen (left), Managing Director, [...]
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
21/05/2026
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-dosing – – No relapses to-date [...]
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
21/05/2026
WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
21/05/2026
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company [...]
The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do
21/05/2026
A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTA VIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who [...]
EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference
21/05/2026
, May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4 th , 2026 AUSTIN, Texas, May 21 th , [...]
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
21/05/2026
SHANGHAI, May 21, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Biodesix to Participate in Upcoming Investor Conferences
21/05/2026
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming [...]
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
21/05/2026
70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024) Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research [...]
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
21/05/2026
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa ( Pa ) Secondary objectives met with no immunogenicity observed, [...]
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
21/05/2026
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten registered offering [...]
Vitacore Announces World-First Custom-Fit CPAP Mask Following Health Canada MDL Approval
21/05/2026
FormFit™ is the world’s first end-to-end custom-fit medical grade silicone CPAP mask, creating a precision fit for each individual face. VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- Vitacore, a deep [...]
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
21/05/2026
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) [...]
Hemab Therapeutics Reports First Quarter 2026 Financial Results
21/05/2026
Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia CAMBRIDGE, Mass. and [...]
Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting
21/05/2026
ORION CORPORATION PRESS RELEASE 21 MAY 2026 at 10:30 EEST Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM - 212 at the 2026 ASCO® Annual Meeting First clinical data from [...]
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
21/05/2026
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “ Nanobiotix ” or the “ Company ”), a late-clinical stage biotechnology company pioneering physics-based [...]

Pages